Sangamo Therapeutics Inc $ 10.65 0.28 (2.7%)
Sangamo Therapeutics Inc News and Headlines -
With sales of $1.6 billion over the past year, BioMarin Pharmaceutical Inc. (BMRN) will get a hefty revenue boost with the introduction of its hemophilia A therapy, which is expected later this year.
Valrox is forecast to reach sales of more than $1.2 billion by 2024, according to pharmaceutical intelligence provider Evaluate. The San Francisco-based biotech’s application is currently being reviewed by regulators in the U.S. and Europe.
In anticipation of a 2020 launch, the company is gearing up manufacturing at its Novato, California plant, more than doubling capacity to 10,000 doses.
The upgrade is important “because first-mover advantage in
Takeda Pharmaceutical Co. Ltd. (TAK) is banking heavily on its gene and cell therapy programs. It’s going to take a while to learn how well they work, but in the meantime, patient investors can enjoy the luxury of a dividend that yields 4%.
The Japanese company’s gene and cell therapies are currently in the early stages of testing. Gene therapy is done by transplanting normal genes into cells in place of missing or defective ones in order to correct genetic disorders. Gene and cell therapies are seen as two technologies that scientists hope can be used to treat many rare
According to the GuruFocus All-In-One Screener, the following health care stocks are popular among gurus.
Four gurus have positions in Corcept Therapeutics Inc. (CORT) with a total weight of 0.13% on their portfolios.
The biotechnology company has a market cap of $1.83 billion. Its revenue grew 64% over the past 12 months and its EPS increased 625%.
The stock is trading with a price-earnings (P/E) ratio of 55.42. The current stock price of $16.07 is 21.43% below its 52-week high and 143.58% above its 52-week low. Over the past decade, it has returned a gain of 458%.
On April 29, Joshua Schimmer of Piper Jaffray released a report highlighting several biopharmaceutical companies tackling sickle cell disease, or SCD. The hereditary blood disorder is recognized by abnormal hemoglobin in the blood. Schimmer believes that to cure SCD with gene therapy, only “a very small percentage of the cells need to be successfully corrected to essentially stop the disease process.” The analyst believes that Bluebird Bio (BLUE) and Biogen (BIIB) have therapies that should “prove successful for patients,” but he has unique considerations for each.
|2020-10-13 $ 11.38 (1.97%)|
$SGMO - Sizing Up Sangamo Therapeutics. Sizing Up Sangamo Therapeutics - seekingalpha.com
|2020-10-06 $ 9.7 (-0.82%)|
|2020-09-09 $ 10.43 (2.25%)|
CRISPR Stocks: Buy or Trade? - www.zacks.com
|2020-08-20 $ 11.66 (-4.58%)|
BioMarin Down on CRL From FDA for Hemophilia A Candidate - www.zacks.com
|2020-08-05 $ 11.5 (0.52%)|
|2020-07-29 $ 9.9 (-1.3%)|
|2020-07-22 $ 11.13 (0.54%)|
Biogen (BIIB) Beats on Q2 Earnings, Raises EPS View, Stock Up - www.zacks.com
|2020-07-13 $ 10.26 (-4.02%)|
$SGMO - Sangamo 2H 2020 Preview. Sangamo 2h 2020 Preview - seekingalpha.com
|2020-07-09 $ 10.89 (2.64%)|
3 Top Biotech Stocks to Watch in July - www.fool.com
|2020-06-18 $ 9.42 (-13.18%)|
|2020-06-16 $ 11.35 (3.37%)|
Better Buy: CRISPR Therapeutics vs. Sangamo Therapeutics - www.fool.com
|2020-05-12 $ 9.79 (8.06%)|
|2020-05-11 $ 9.06 (4.14%)|
|2020-05-05 $ 8.76 (4.53%)|
|2020-04-29 $ 8.54 (4.15%)|
Better Buy: Cara Therapeutics vs. Sangamo Therapeutics - www.fool.com
|2020-04-14 $ 7.49 (4.76%)|
|2020-04-01 $ 6.21 (-2.51%)|
Better Buy: Editas Medicine vs Sangamo Therapeutics - www.fool.com
3 Top Stocks You've Probably Never Heard Of - www.fool.com
|2020-03-25 $ 6.26 (0.81%)|
|2019-02-21 $ 8.54 (0.95%)|
|2010-11-03 $ 4.03 (-1.47%)|
|2010-08-05 $ 3.8 (-2.31%)|
|2010-05-05 $ 5.27 (-7.05%)|
|2009-11-06 $ 6.35 (-0.78%)|
|2009-08-03 $ 5.86 (2.81%)|
|2009-05-06 $ 3.61 (-8.14%)|